SMS Pharmaceuticals has received a favorable ruling from the Commissioner of Income-tax, cancelling a previously contested tax demand of Rs 45.63 crore for the 2023-24 assessment year. This decision removes a significant financial burden...
Zydus Lifesciences has announced a leadership transition in its International Markets unit. Dr. Amrut Naik will resign as President on November 7, 2026, with industry veteran Christoph Stoller appointed to the role effective November 2,...
Rainbow Children's Medicare reported a strong second quarter for FY27, with revenue growing to Rs 543.02 crore and net profit reaching Rs 83.89 crore. The company is actively expanding its footprint through a new hospital project in Mumb...
Broach Lifecare Hospital reported a revenue of Rs 3.86 crore for the half-year ending September 2026, a jump from Rs 2.60 crore in the same period last year. However, net profit declined to Rs 0.13 crore from Rs 0.31 crore due to rising...
Hindustan Bio Sciences has reported a net profit of Rs 31.04 lakh for the quarter ended September 2026, marking a turnaround from a loss in the previous quarter. The company also announced the resignation of its Company Secretary, Mr. Sh...
Transgene Biotek has reported the resignation of its statutory auditor, M/s Eswara Rao & Co., effective October 28, 2026. This is the second auditor resignation for the company this month. The auditor cited medical emergencies and time c...
Advanced Enzyme Technologies reported a consolidated net profit of Rs 483.06 million for Q2 FY27, up from Rs 433.26 million year-on-year. The company also announced the successful completion of its open-market share buyback, utilizing 99...
Granules India's Gagillapur facility faces 11 USFDA observations following a recent inspection. Management confirmed no impact on current product manufacturing or distribution, with plans to submit a corrective action plan within 15 days.
Corona Remedies posted strong H1 FY27 results with revenue at Rs 863.6 crore, up 22% YoY. EBITDA margins improved to 21.9%, supported by the company's focus on chronic therapies and new regulatory certifications for its Bhayla plant.